300573 Shenyang Xingqi Pharmaceutical
- 158.21
- +3.31+2.14%
Shenyang Xingqi Pharmaceutical News
Here's Why We Think Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as
Individual Investors Are Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Biggest Owners and Were Hit After Market Cap Dropped CN¥3.3b
Key Insights Significant control over Shenyang Xingqi PharmaceuticalLtd by individual investors implies that the general public has more power to influence management and governance-related decisions
Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Sinqi Pharmaceutical (300573.SZ): There is currently no medicine to treat flying mosquito disease
Gelonghui, May 28 | An investor asked Sinqi Pharmaceutical (300573.SZ) on the investor interactive platform, “Please ask if your company has any drugs or R&D projects to treat “flying mosquito disease.” The company replied that the company currently has no drugs to treat flying mosquito disease.
Sinqi Pharmaceutical (300573.SZ): 2023 equity distribution 10 to 4 distribution of 30 yuan equity registration date May 21
Gelonghui, May 14 | Sinqi Pharmaceutical (300573.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 30.000000 in cash (tax included) to all shareholders for every 10 shares based on the company's total share capital excluding 124,589,194 shares after 0 shares have been repurchased. At the same time, the capital reserve fund was used to transfer 4.000000 shares to all shareholders for every 10 shares. The share registration date for this equity distribution is May 21, 2024; the exclusive dividend date is May 22, 2024.
After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar
Despite an already strong run, Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) shares have been powering on, with a gain of 31% in the last thirty days. The annual gain comes to 144% followin
Is Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Latest Stock Performance A Reflection Of Its Financial Health?
Most readers would already be aware that Shenyang Xingqi PharmaceuticalLtd's (SZSE:300573) stock increased significantly by 71% over the past three months. Given the company's impressive performance
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%
Shenyang Xingqi Pharmaceutical's (SHE:300573) attributable profit rose 80% to 34.7 million yuan in the first quarter from 19.3 million yuan in the year-ago period, according to a Friday filing with th
Sinqi Pharmaceutical (300573.SZ): Net profit of 347.48,900 yuan in the first quarter increased 79.59% year-on-year
Gelonghui, April 25 | Sinqi Pharmaceutical (300573.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 349.9 million yuan, up 22.10% year on year; net profit attributable to shareholders of listed companies was 347.489 million yuan, up 79.59% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 35.2409 million yuan, up 126.46% year on year; basic earnings per share were 0.28 yuan.
Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Sheds 3.4% This Week, as Yearly Returns Fall More in Line With Earnings Growth
We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to find, but they can generate massive returns over long periods. Just think abou
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher
Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. The ann
Changes in Hong Kong stocks | Okanvision Bio-B (01477) is now up more than 7% Sinqi Eye Medication Atropine Eye Drops Approved Clinical Trials of Listed Companies' Products Previously Approved
Okanvision Bio-B (01477) is now up more than 7%. As of press release, it is up 7.57% to HK$5.97, with a turnover of HK$10.8087 million.
Sinqi Pharmaceutical (300573.SZ): Received a drug registration certificate for atropine sulfate eye drops
Gelonghui announced on March 11: Sinqi Pharmaceutical (300573.SZ). Today, Shenyang Xingqi Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for atropine sulfate eye drops approved and issued by the State Drug Administration. The company's development code for atropine sulphate eye drops is SQ-729. This product is an ophthalmic preparation with atropine sulfate as the active ingredient. The approved clinical indication is that this product is used to slow the progression of myopia in children aged 6 to 12 with spherical specular intensity of -1.00D to -4.00D (astigmatism ≤ 1.50D, refractive error ≤ 1.50D). Currently, there are no myopia-related indications in China
Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Surges 7.4%; Individual Investors Who Own 48% Shares Profited Along With Insiders
Key Insights Significant control over Shenyang Xingqi PharmaceuticalLtd by individual investors implies that the general public has more power to influence management and governance-related decisions
Sinqi Pharmaceutical (300573.SZ): Currently, the company has no drugs to treat pediatric astigmatism
Gelonghui, Feb. 27丨Sinqi Pharmaceutical (300573.SZ) said on the investor interactive platform that currently the company has no drugs to treat astigmatism in children. In the future, the company will continue to enrich its product pipeline to meet the pharmaceutical needs of the ophthalmology market.
Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Is Weakness In Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) has had a rough month with its share price down 5.6%. But if you pay close attention, you might gather that its strong financials could mean that the
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Shares May Have Run Too Fast Too Soon
When close to half the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.8x, you may consider Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) as a
Sinqi Pharmaceutical (300573.SZ): 33 products continue to be included in the national health insurance catalogue
<国家基本医疗保险、工伤保险和生育保险药品目录 (2023年) >Gelonghui, December 14|Xingqi Pharmaceutical (300573.SZ) announced that on December 13, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Notice on Issuance” (Health Insurance Development [2023] No. 30). This time, the company has a total of 33 products that continue to be included in the national health insurance catalogue, including 8 category A and 25 category B. Various products such as ciclosporin eye drops (II), compound electrolyte intraocular rinse, and sodium hyaluronate eye drops continue to be included in the “National Medical Insurance Catalogue”. This time, the company did not have one
Insiders Own 31% of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares but Retail Investors Control 44% of the Company
Key Insights Significant control over Shenyang Xingqi PharmaceuticalLtd by retail investors implies that the general public has more power to influence management and governance-related decisions A
Analysis
Price Target
No Data
